Hi-Fil® Lutein Achieves GRAS Status

Hi-Fil® Lutein Achieves GRAS Status Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava Manufacturer of Ephedra-Based Dietary Supplements Settles Lawsuit with State N.V.E. Pharmaceuticals, and Robert Occhifinto, the president of N.V.E., have settled a lawsuit that alleged the Sussex County manufacturer of dietary supplements misled consumers by making false and misleading claims about the safety and efficacy of its products. The settlement requires N.V.E. and Occhifinto to pay the State $260,000 as follows: a $60,000 payment from Occhifinto and four $50,000 payments from N.V.E. Manufacturer of Ephedra-Based Dietary Supplements Settles Lawsuit with State N.V.E. Pharmaceuticals, and Robert Occhifinto, the president of N.V.E., have settled a lawsuit that alleged the Sussex County manufacturer of dietary supplements misled consumers by making false and misleading claims about the safety and efficacy of its products. The settlement requires N.V.E. and Occhifinto to pay the State $260,000 as follows: a $60,000 payment from Occhifinto and four $50,000 payments from N.V.E. FDA Notifies Consumers of Restitution Program for Purchases of Lane Labs' Products The Food and Drug Administration (FDA) is notifying consumers of a restitution (refund) program for purchasers of three of Lane Labs-USA, Inc.'s products, BeneFin, MGN-3 and SkinAnswer, under which consumers who purchased those products between September 22, 1999 and July 12, 2004 are eligible for a partial refund of the purchase price and any shipping and handling costs. FDA Notifies Consumers of Restitution Program for Purchases of Lane Labs' Products The Food and Drug Administration (FDA) is notifying consumers of a restitution (refund) program for purchasers of three of Lane Labs-USA, Inc.'s products, BeneFin, MGN-3 and SkinAnswer, under which consumers who purchased those products between September 22, 1999 and July 12, 2004 are eligible for a partial refund of the purchase price and any shipping and handling costs. Appeals Court Rules for FDA in Ephedra Ban: Overturns Lower Court Finding in Nutraceutical v. von Eschenbach A three-judge panel of the 10th Circuit U.S. Court of Appeals ruled yesterday in favor of the U.S. Food and Drug Administration (FDA) in a case that had challenged the agency's 2004 prohibition of any level of ephedrine in dietary supplements. "The evidence in the administrative record was sufficiently probative to demonstrate by a preponderance of the evidence that EDS [ephedrine dietary supplements] at any dose level pose an unreasonable risk. The greater weight of the evidence supports the FDA’s ban on EDS, thus satisfying the agency's burden." Appeals Court Rules for FDA in Ephedra Ban: Overturns Lower Court Finding in Nutraceutical v. von Eschenbach A three-judge panel of the 10th Circuit U.S. Court of Appeals ruled yesterday in favor of the U.S. Food and Drug Administration (FDA) in a case that had challenged the agency's 2004 prohibition of any level of ephedrine in dietary supplements. "The evidence in the administrative record was sufficiently probative to demonstrate by a preponderance of the evidence that EDS [ephedrine dietary supplements] at any dose level pose an unreasonable risk. The greater weight of the evidence supports the FDA’s ban on EDS, thus satisfying the agency's burden." Appeals Court Rules for FDA in Ephedra Ban: Overturns Lower Court Finding in Nutraceutical v. von Eschenbach A three-judge panel of the 10th Circuit U.S. Court of Appeals ruled yesterday in favor of the U.S. Food and Drug Administration (FDA) in a case that had challenged the agency's 2004 prohibition of any level of ephedrine in dietary supplements. "The evidence in the administrative record was sufficiently probative to demonstrate by a preponderance of the evidence that EDS [ephedrine dietary supplements] at any dose level pose an unreasonable risk. The greater weight of the evidence supports the FDA’s ban on EDS, thus satisfying the agency's burden." FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. FDA Statement on Tenth Circuit’s Ruling to Uphold FDA Decision Banning Dietary Supplements Containing Ephedrine Alkaloids FDA states that no dosage of dietary supplements containing ephedrine alkaloids is safe and the sale of these products in the United States is illegal and subject to FDA enforcement action. Government of Canada Awards Site License to Sangster’s Health Centres Sangster’s Health Centres, (a member of Planet Organic Health Corp. POH-TSX Venture Exchange), announces that Darwen Holdings, the product distribution division of Sangster’s Health Centres has been awarded a site license under The Government of Canada’s Natural Health Products Regulations (NHP). Government of Canada Awards Site License to Sangster’s Health Centres Sangster’s Health Centres, (a member of Planet Organic Health Corp. POH-TSX Venture Exchange), announces that Darwen Holdings, the product distribution division of Sangster’s Health Centres has been awarded a site license under The Government of Canada’s Natural Health Products Regulations (NHP). Government of Canada Awards Site License to Sangster’s Health Centres Sangster’s Health Centres, (a member of Planet Organic Health Corp. POH-TSX Venture Exchange), announces that Darwen Holdings, the product distribution division of Sangster’s Health Centres has been awarded a site license under The Government of Canada’s Natural Health Products Regulations (NHP). AHPA Submits Comments to US Forest Service on Native Plants Proposal AHPA has submitted comments to the US Forest Service (USFS) last Friday, specifically to request that the term "native plant" be defined in language that is consistent with other federal definitions of the term, and to suggest greater clarity in a newly proposed policy statement. (May 26 USFS proposal to establish a new directive in Forest Service Manual 2070 for native plant materials.) AHPA Submits Comments to US Forest Service on Native Plants Proposal AHPA has submitted comments to the US Forest Service (USFS) last Friday, specifically to request that the term "native plant" be defined in language that is consistent with other federal definitions of the term, and to suggest greater clarity in a newly proposed policy statement. (May 26 USFS proposal to establish a new directive in Forest Service Manual 2070 for native plant materials.) Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. Consumer Protection Deputy Director To Leave FTC C. Lee Peeler, deputy director of the Bureau of Consumer Protection for the past five years, will leave the FTC, to become president of the National Advertising Review Council and Executive Vice President for National Advertising and Self-Regulation of the Council of Better Business Bureaus. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. UK: Comments wanted on phytosterol French company, DRT, has asked for a decision on its phytosterol ingredient, which is derived from tall oil pitch – a substance distilled from pine resin. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. TGA Approves EPAX’S Omega-3 Oils For Use In Australia’s Complementary Medicine Products Company announced that after 18 months of working closely with its Australian distributor Pathway International, it has been granted regulatory approval from Australia’s Therapeutic Goods Administration (TGA), allowing EPAX’s range of omega-3 oils to be used in complementary medicine products in Australia. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Cargill Expands GRAS Status of Oliggo-Fiber® Inulin and Oligofructose Products Company has expanded the GRAS (Generally Recognized As Safe) status of its Oliggo-Fiber® brand of inulin and oligofructose products through an independent evaluation by a qualified scientific expert, permitting the Oliggo-Fiber inulin and oligofructose line of products for general use in foods at levels consistent with current good manufacturing practice. Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma. Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma. Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma. Sabinsa Secures Approval From Government of India to Use Its Ocufors(TM) Eye Drop Solution for Glaucoma Treatment Company has been granted permission by the Drugs Controller General of India to manufacture and market Ocufors(TM), an ophthalmic solution containing one percent forskolin, for the treatment of glaucoma. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. GRAS Status Affirmed for Lipogen Phosphatidylserine Company announces that FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. NSF International Awards First GMP for Sport(TM) Registration to Century Foods International NSF International announced that Century Foods International is the first manufacturing facility to receive Good Manufacturing Practices (GMP) for Sport™ registration, a new program that builds on NSF’s GMP Registration Program. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. FDA Asks U.S. Marshals to Seize Dietary Supplements Products Being Promoted With Drug Claims At the request of the U.S. Food and Drug Administration (FDA), on September 5, 2006, U.S. Marshals seized quantities of Ellagimax capsules, Coral Max capsules, Coral Max without Iron capsules, and Advanced Arthritis Support capsules distributed by Advantage Nutraceuticals L.L.C. of Fort Walton Beach, Florida, valued at approximately $55,000.00. The products are alleged to be in violation of the new drug and misbranding provisions of the Federal Food, Drug and Cosmetic Act. DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet. DEA: Hi-Tech Pharmaceuticals & 11 Individuals Indicted for "Generic" Pill Fraud Scheme Hi-Tech Pharmaceuticals & 11 Individuals have been indicted by a federal grand jury on multiple felony charges relating to a scheme to sell adulterated and unapproved new drugs over the internet. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Navamedic’s product Glucomed®/Flexove(TM) approved in EU by CHMP Navamedic has received notice that its glucosamine HCl product Glucomed®/Flexove(TM) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP). The approval will be valid for all 25 EU/EEA countries in Navamedic’s application. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. Ontario Government Closer to Regulating Traditional Chinese Medicine Ontario has moved closer to regulating traditional Chinese medicine (TCM) and acupuncture as the proposed legislation moved to second reading. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. FDA Authorizes Qualified Health Claim for Canola Oil The U.S. Food and Drug Administration has announced that canola oil is now eligible to bear a qualified health claim on its ability to reduce the risk of coronary heart disease (CHD) due to its unsaturated fat content. The claim, which canola oil bottlers and makers of eligible products* may use on labels, states: Limited and not conclusive scientific evidence suggests that eating about 1 1/2 tablespoons (19 grams) of canola oil daily may reduce the risk of coronary heart disease due to the unsaturated fat content in canola oil. To achieve this possible benefit, canola oil is to replace a similar amount of saturated fat and not increase the total number of calories you eat in a day. One serving of this product contains [x] grams of canola oil. Tate & Lyle Interim Results Announcement 2009 Tate & Lyle has announced their 2009 Interim results, reporting the Group's performance, before the impact of exchange translation, remains on track to meet our expectations for the full year. NPI Daily - Top of The News for Nov. 6, 2009 - National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters Nature's Sunshine Products Reports FY09 Q3 Operating Results; SunOpta Announces FY09 Q3 Results; Tate & Lyle Interim Results Announcement 2009; NOW Foods Receives the 2009 Illinois Governor's Sustainability Award; Transport-C Supports Vitamin Angels at SSW; Cantox at Supplyside West; New Support Showing Immunoglobulin Supplementation Enhances Immune System; FDA Warning: Over-the-Counter Sex Enhancement Drug May Cause 'Dangerously' Low Blood Pressure; EPAX AS Achieves 'Friend of the Sea' Certification; National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters; Fast-C™ At SupplySide West: US Clinical Trials Data Available In Booth ; Nutty Flavor & Healthy Boost of Omega-3 Make Hemp Seed an Ideal Ingredient; DSM's tensVida® Recognized for Innovative Development; Nutrition 21 Announces Addition of Innovative New Probiotic + Omega-3 Fish Oil Combination Product; Glanbia Nutritionals Offers More Than Ingredients for Nutritional Beverages; Whole Foods Market(R) Offers Natural Solutions to Help Build Up Body Defenses With Immune System Support; Doug Reyes Joins Embria as Regional Sales Manager; Michael F. Hines Joins Board of General Nutrition Centers, Inc.; Dr. Arnold Hirsch Celebrates 50th Anniversary with the American Chemical Society NPI Daily - Top of The News for Nov. 6, 2009 - National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters Nature's Sunshine Products Reports FY09 Q3 Operating Results; SunOpta Announces FY09 Q3 Results; Tate & Lyle Interim Results Announcement 2009; NOW Foods Receives the 2009 Illinois Governor's Sustainability Award; Transport-C Supports Vitamin Angels at SSW; Cantox at Supplyside West; New Support Showing Immunoglobulin Supplementation Enhances Immune System; FDA Warning: Over-the-Counter Sex Enhancement Drug May Cause 'Dangerously' Low Blood Pressure; EPAX AS Achieves 'Friend of the Sea' Certification; National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters; Fast-C™ At SupplySide West: US Clinical Trials Data Available In Booth ; Nutty Flavor & Healthy Boost of Omega-3 Make Hemp Seed an Ideal Ingredient; DSM's tensVida® Recognized for Innovative Development; Nutrition 21 Announces Addition of Innovative New Probiotic + Omega-3 Fish Oil Combination Product; Glanbia Nutritionals Offers More Than Ingredients for Nutritional Beverages; Whole Foods Market(R) Offers Natural Solutions to Help Build Up Body Defenses With Immune System Support; Doug Reyes Joins Embria as Regional Sales Manager; Michael F. Hines Joins Board of General Nutrition Centers, Inc.; Dr. Arnold Hirsch Celebrates 50th Anniversary with the American Chemical Society Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Gencor Announces Study Results Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men. Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009 Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine. Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009 Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine. Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009 Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine. Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009 Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine. Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009 Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine. Sharp-GPC™ 45F by Enzymotec Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline. Sharp-GPC™ 45F by Enzymotec Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline. Sharp-GPC™ 45F by Enzymotec Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline. Sharp-GPC™ 45F by Enzymotec Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline. Sharp-GPC™ 45F by Enzymotec Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline. Sharp-GPC™ 45F by Enzymotec Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline. Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials. Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials. Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials. Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials. Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials. Taming Fear of the H1N1 Flu Vaccine Taming Fear of the H1N1 Flu Vaccine Natural Cold and Flu Remedies: Do They Help? Natural Cold and Flu Remedies: Do They Help? Exercise as Pain Therapy Exercise as Pain Therapy	Designation Assures Customers of Safety for Use in Food and Beverages Florida, NY, August 10, 2006 –Hi-Fil® Lutein products, manufactured by Industrial Organica and distributed exclusively by Pharmline Inc., has attained self-affirmed GRAS (Generally Recognized As Safe) status, through an independent evaluation by an expert panel of scientists. This designation permits the incorporation of Hi-Fil in a variety of foods and beverages. Industrial Organica (IOSA), a leading manufacturer of a patented line of lutein and zeaxanthin products marketed under the Hi-Fil label, has been producing carotenoids in their cGMP facility since 1966. Sensing a market demand, IOSA conducted a review by an independent panel of scientific experts to determine the feasibility of Hi-Fil Lutein in food and beverage products applications. After comprehensive review, the panel unanimously agreed to award GRAS status, affirming the safety of the ingredient as an additive. Greg Berthomieu, business development manager at Pharmline Inc. believes the GRAS determination, along with the pre-existing kosher approval of Hi-Fil Lutein products, significantly increases the market for this ingredient. “The aging population concerned with maintaining an active lifestyle has a high level of awareness about the benefits of lutein. The ability to safely add this ingredient and feature it in cereals, energy and sports drinks, energy bars, yogurts and other food and beverages, will drive consumer demand for these products,” said Mr. Berthomieu. Research has demonstrated the important potential roles of lutein and zeaxanthin in maintaining healthy eyes. Studies suggest that these compounds may reduce the risk of age-related eyesight problems, such as age-related macular degeneration (AMD) and cataracts. Pharmline Inc., is the exclusive distributor of Hi-Fil Lutein products. All popular Hi-Fil products are warehoused in Pharmline’s state-of-the-art facility in Florida, NY with quick delivery available only a few days from order date. Contact: Greg Berthomieu, Ph 845.651.4443, GBerthomieu@pharmlineinc.com Pharmline Inc. is a leading global supplier and manufacturer of high-quality nutraceutical and functional food ingredients. Founded in 1986, the company specializes in custom formulations, large capacity blending of liquids, powders and granulations. In addition to these services, Pharmline maintains sales and representation agreements with manufacturers of natural products and fine chemicals in over 18 countries around the world and has business affiliations with: EPAX AS, Norway; Kowa Company LTD., Japan; Burgundy Botanical Extracts, France; and Industrial Organica, Mexico. With over 250 products, including Hi-Fil Lutein, Zeaxanthin, EPAX Omega 3 and Burgundy Grape extracts, Pharmline is committed to providing its customers with the highest level of innovation, technology, research & development and quality assurance. Pharmline Inc. is GMP certified by the Natural Products Association (formerly NNFA). To learn more about Hi-Fil® Lutein, contact Pharmline Inc. at info@pharmlineinc.com or (845) 651-4443.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software